Abstract 200P
Background
Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the Survival of hepatocellular carcinoma (HCC) patients receiving TACE remains challenging.
Methods
This retrospective study included 1805 HCC patients receiving TACE. Each patient was randomized to a training set (n = 1264) and a validation set (n = 541). We investigated prognostic factors in the training set and developed an easily applicable ALFP (ALBI grade, AFP, and Prothrombin time) score, which was evaluated in the validation set.
Results
We built the ALFP score using baseline ALBI grade 2 or 3 (HR 1.301, 95% CI 1.073-1.577,p = 0.007) and AFP ≥ 100 ng/ml (HR 1.328, 95% CI 1.133-1.557, p < 0.001)and PT 13.1 s (HR 1.262, 95% CI 1.047-1.521, p=0.015), which were identified as unfavorable prognosis factors in a multivariate analysis. The median OS in patients with ALFP scores of 0, 1, 2, and 3 points was 50.1 months (95% CI NA), 33.6months (95% CI 27.4–39.8), and 20.4months (95% CI 18.0–22.8), and 12.7 months (95% CI 10.2–15.2), respectively; the difference was statistically significant (p < 0.001).the result were confirmed in the validation set(The median OS ,0/1/2/3 points = 42.5/32.6/20.4 /13.0 months, p < 0.0019).
Conclusions
The ALFP score can predict the prognosis of HCC patients receiving TACE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiong Chen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract